6876 Federal Register / Vol. 81, No. 26 / Tuesday, February 9, 2016 / Notices 

associated with the grant applications, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Transcatheter Cavopulmonary Bypass 

Endograft. 

Date: March 2, 2016. 

Time: 9:30 a.m. to 12:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Room 7182, Bethesda, MD 

20892, (Telephone Conference Call). 

Contact Person: Susan Wohler Sunnarborg, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review/DERA, National, Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7182, Bethesda, MD 20892, 

sunnarborgsw@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Career Development Program to Promote 

Diversity in Health Research. 

Date: March 4, 2016. 

Time: 8:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The River Inn, 924 25th Street NW., 

Washington, DC 20037. 

Contact Person: Stephanie L. Constant, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7189, Bethesda, MD 20892, 301– 

443–8784, constantsl@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 3, 2016. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–02458 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Neurogenesis and 

Cell Fate Study Section, February 18, 

2016, 08:00 a.m. to February 19, 2016, 

02:00 p.m., Hotel Kabuki, 1625 Post 

Street, San Francisco, CA, 94115 which 

was published in the Federal Register 

on January 26, 2016, 81 FR 4316–4317. 

The meeting will be held on February 

18, 2016 from 8:00 a.m.–8:00 p.m. The 

meeting location remains the same. The 

meeting is closed to the public. 

Dated: February 3, 2016. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–02455 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; BD2K RFAs: 

Courses for Skills Development and Open 

Educational Resources for Biomedical Big 

Data (R25). 

Date: March 2, 2016. 

Time: 12:00 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Kee Hyang Pyon, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5148, 

MSC 7806, Bethesda, MD 20892, 

pyonkh2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Oncology. 

Date: March 3–4, 2016. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Juraj Bies, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Dr., Rm. 4158, MSC 7806, Bethesda, MD 

20892, 301–435–1256, biesj@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 12– 

251: Behavioral Science Track Award for 

Rapid Transition Review. 

Date: March 3, 2016. 

Time: 11:30 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Serena Chu, Ph.D., 

Scientific Review Officer, BBBP IRG, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3178, 

MSC 7848, Bethesda, MD 20892, 301–500– 

5829, sechu@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 3, 2016. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–02454 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request; Drug 

Accountability Report Form and 

Investigator Registration Procedure in 

the Conduct of Investigational Trials 

for the Treatment of Cancer (NCI) 

SUMMARY: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Cancer Institute, the National Institutes 

of Health, has submitted to the Office of 

Management and Budget (OMB) a 

request for review and approval of the 

information collection listed below. 

This proposed information collection 

was previously published in the Federal 

Register on November 17, 2015 page 

71815 and allowed 60 days for public 

comment. No public comments were 

received. The purpose of this notice is 

to allow an additional 30 days for public 

comment. The National Cancer Institute, 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974, Attention: NIH 

Desk Officer. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 81, No. 26 / Tuesday, February 9, 2016 / Notices 6877 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, or request more 

information on the proposed project, 

contact: Charles Hall, RPh, M.S., Chief, 

Pharmaceutical Management Branch, 

Cancer Therapy Evaluation Program, 

National Cancer Institute, 9609 Medical 

Center Drive, RM 5W240, MSC 9725, 

Bethesda, Maryland 20892. Or call nontoll-free number (240) 276–6575, or 

email your request, include your 

address to: hallch@mail.nih.gov. 

Formal requests for additional plans 

and instruments must be requested in 

writing. 

Proposed Collection: Drug 

Accountability Report Form and 

Investigator Registration Procedure in 

the Conduct of Investigational Trials for 

the Treatment of Cancer, 0925–0613, 

Expiration Date 03/31/2016, Revision, 

National Cancer Institute (NCI), 

National Institutes of Health (NIH). 

Need and Use of Information 

Collection: The U.S. Food and Drug 

Administration (FDA) holds the 

National Cancer Institute (NCI) 

responsible, as a sponsor of 

investigational drug trials, for the 

collection of information about the 

clinical investigators who participate in 

these trials and to assure the FDA that 

systems for accountability are being 

maintained by investigators in its 

clinical trials program. The information 

collected is used to identify qualified 

investigators and to facilitate the 

submission and distribution of 

important information relative to the 

investigational drug and the response of 

the patient to that drug. Investigators are 

physicians who specialize in the 

treatment of patients with cancer. Data 

obtained from the Drug Accountability 

Record is used to track the dispensing 

of investigational anticancer agents from 

receipt from the NCI to dispensing or 

administration to patients. NCI and/or 

its auditors use this information for 

compliance purposes. The frequency of 

Response is up to 16 times per year. The 

affected public is private sector 

including businesses, other for-profit 

organizations, and non-profit 

institutions. The type of respondents are 

investigators, pharmacists, nurses, 

pharmacy technicians, and data 

managers. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

14,649 hours. 

TABLE 1—ESTIMATES OF ANNUAL BURDEN

Estimated annualized burden hours 

Type of 

respondents Form Number of respondents 

Number of 

responses 

Average time 

per response 

(in hours) 

Total hour 

burden 

Investigators and Designee for Investigator Registration and DARF.Statement of Investigator ................. 22,283 1 15/60 5,571 

NCI/DCTD/CTEP Supplemental Investigator.22,283 1 10/60 3,714 

Financial Disclosure Forms .............. 22,283 1 5/60 1,857 

NCI/DCTD/CTEP Drug Accountability Record Form (DARF and 

DARF-Oral).

3,288 16 4/60 3,507 

Total ........................................... ........................................................... 25,571 119,457 ........................ 14,649 

Dated: February 3, 2016. 

Karla Bailey, 

Project Clearance Liaison, National Cancer 

Institute, NIH. 

[FR Doc. 2016–02447 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NST1 Member Conflict SEP. 

Date: March 8, 2016. 

Time: 9:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Arlington, 1325 Wilson 

Boulevard, Arlington, VA 22209. 

Contact Person: William C Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

0660, benzingw@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS R 35 Review. 

Date: March 17–18, 2016. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Natalia Strunnikova, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Research, NINDS/NIH/DHHS/Neuroscience 

Center, 6001 Executive Boulevard, Suite 

3208, MSC 9529, Bethesda, MD 20892–9529, 

301–402–0288, Natalia.strunnikova@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS R35 Review. 

Date: March 17–18, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Ernest W Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

4056, lyonse@ninds.nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES